Leo-pharma A/s

Tina Dahlerup Poulsen

Anthony Murray

Jakob Felding

Xifu Liang

Erik Rytter Ottosen

Daniel Rodriguez Greve

Simon Feldbæk Nielsen

Anne Marie Horneman

Gunnar Grue-Sørensen

Søren Christian Schou

Jens Christian Højland Larsen

Carsten Ryttersgaard

The invention relates to compounds of general formula (I) wherein A, R, R, R, R, R, R, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation. 

Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors

The invention relates to compounds of general formula (I) wherein W, D, E, G, J, L, R, R, R, R, Rand Y are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer and skin and eye diseases. 

VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof

Growing community of inventors

Brønshøj, Denmark

Tina Dahlerup Poulsen